Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: How the latest results are improving therapeutic options

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 6, 2015, Pages 321-339

  Jiang, Hanfang ^a   Rugo, Hope S ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ado trastuzumab emtansine; Breast cancer; HER2; Lapatinib; Pertuzumab

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; AFATINIB; ALPELISIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CIXUTUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; MARGETUXIMAB; MM 302; NERATINIB; PERTUZUMAB; PILARALISIB; TASELISIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUCATINIB; UNCLASSIFIED DRUG;

BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84945137973     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015599389     Document Type: Review

References (89)

1. Agus D. Akita R. Fox W. Lewis G. Higgins B. Pisacane P. et al. (2002) Targeting ligand-activated ErbB 2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127–137.
2. Andersson M. Lopez-Vega J. Petit T. Zamagni C. Freudensprung U. Robb S. et al. (2014) Interim safety and efficacy of pertuzumab, trastuzumab and vinorelbine for first-line (1l) treatment of patients (pts) with HER2-positive locally advanced or metastatic breast cancer (MBC). Ann Oncol 25: iv116–iv136.
3. André F. O'Regan R. Ozguroglu M. Toi M. Xu B. Jerusalem G. et al. (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15: 580–591.
4. Bachelot T. Romieu G. Campone M. Dieras V. Cropet C. Dalenc F. et al. (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14: 64–71.
5. Bartsch R. Berghoff A. Preusser M. (2014) Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 116: 205–206.
6. Bartsch R. Wenzel C. Altorjai G. Pluschnig U. Rudas M. Mader R. et al. (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25: 3853–3858.
7. Baselga J. Cortés J. Im S. Clark E. Ross G. Kiermaier A. et al. (2014) Biomarker analyses in cleopatra: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32: 3753–3761.
8. Baselga J. Cortés J. Kim S. Im S. Hegg R. Im Y. et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109–119.
9. Baselga J. Gelmon K. Verma S. Wardley A. Conte P. Miles D. et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144.
10. Berns K. Horlings H. Hennessy B. Madiredjo M. Hijmans E. Beelen K. et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402.
11. Blackwell K. Burstein H. Storniolo A. Rugo H. Sledge G. Aktan G. et al. (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF 104900 study. J Clin Oncol 30: 2585–2592.
12. Blackwell K. Burstein H. Storniolo A. Rugo H. Sledge G. Koehler M. et al. (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–1130.
13. Borges V. Hamilton E. Yardley D. Chaves J. Aucoin N. Ferrario C. et al. (2015) A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC). Cancer Res 32: abstract TPS662.
14. Bose R. Kavuri S. Searleman A. Shen W. Shen D. Koboldt D. et al. (2013) Activating HER 2 mutations in HER 2 gene amplification negative breast cancer. Cancer Discov 3: 224–237.
15. Burris H. Giaccone G. Im S. Bauer T. Oh D. Jones S. et al. (2015) Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors. J Clin Oncol 3 (Suppl.): abstract 523.
16. Burris H. Giaccone G. Im S. Bauer T. Trepel J. Nordstrom J. et al. (2013) Phase I study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER 2 oncoprotein. J Clin Oncol 31(Suppl. 15): abstract 3004.
17. Burstein H. Sun Y. Dirix L. Jiang Z. Paridaens R. Tan A. et al. (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28: 1301–1307.
18. Cameron D. Casey M. Oliva C. Newstat B. Imwalle B. Geyer C. (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15: 924–934.
19. Canonici A. Gijsen M. Mullooly M. Bennett R. Bouguern N. Pedersen K. et al. (2013) Neratinib overcomes trastuzumab resistance in HER 2 amplified breast cancer. Oncotarget 4: 1592–1605.
20. Cortés J. Baselga J. Im Y. Im S. Pivot X. Ross G. et al. (2013) Health-related quality-of-life assessment in cleopatra, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol 24: 2630–2635.
21. Cortés J. Dieras V. Ro J. Barriere J. Bachelot T. Hurvitz S. et al. (2014) Randomized phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and / or lapatinib-based therapy: Lux-Breast 3. Cancer Res 75: P5–19–07.
22. Dang C. Iyengar N. Datko F. D'andrea G. Theodoulou M. Dickler M. et al. (2015) Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33: 442–447.
23. Dieras V. Harbeck N. Budd G. Greenson J. Guardino A. Samant M. et al. (2014) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 32: 2750–2757.
24. Ellis P. Barrios C. Eiermann W. Toi M. Im Y. Conte P. et al. (2015) Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) Vs trastuzumab + taxane (Ht) for first-line treatment of HER2-positive MBC: primary results from the marianne study. J Clin Oncol 33(Suppl): abstract 507.
25. Ellis P. Barrios C. Im Y. Patre M. Branle F. Perez E. (2011) Marianne: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol 29(Suppl): abstract TPS102.
26. Ferrario C. Welch S. Chaves J. Walker L. Krop I. Hamilton E. et al. (2015) Ont-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (Mets). J Clin Oncol 33(Suppl.): abstract 612.
27. Franklin M. Carey K. Vajdos F. Leahy D. de Vos A. Sliwkowski M. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317–328.
28. Gelmon K. Boyle F. Kaufman B. Huntsman D. Manikhas A. Di Leo A. et al. (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33: 1574–1583.
29. Gelmon K. Mackey J. Verma S. Gertler S. Bangemann N. Klimo P. et al. (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5: 52–58; discussion 59–62.
30. Geyer C. Forster J. Lindquist D. Chan S. Romieu C. Pienkowski T. et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743.
31. Gianni L. Eiermann W. Semiglazov V. Lluch A. Tjulandin S. Zambetti M. et al. (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15: 640–647.
32. Gianni L. Romieu G. Lichinitser M. Serrano S. Mansutti M. Pivot X. et al. (2013) Averel: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent / metastatic breast cancer. J Clin Oncol 31: 1719–1725.
33. Giordano S. Temin S. Kirshner J. Chandarlapaty S. Crews J. Davidson N. et al. (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 32: 2078–2099.
34. Goldhirsch A. Gelber R. Piccart-Gebhart M. de Azambuja E. Procter M. Suter T. et al. (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382: 1021–1028.
35. Hamilton E. Yardley D. Hortobagyi G. Walker L. Borges V. Moulder S. (2015 a) A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and / or trastuzumab, in HER2+ metastatic breast cancer (MBC). Cancer Res 75: P4–15–19.
36. Hamilton E. Yardley D. Hortobagyi G. Walker L. Borges V. Moulder S. (2015 b) Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC). J Clin Oncol 33(Suppl.): abstract 602.
37. Harbeck N. Huang C. Hurvitz S. Yeh D. Shao Z. Im S. et al. (2014) Randomized phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-breast 1. Cancer Res 75: P5–19–1.
38. Hicklin D. Ellis L. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011–1027.
39. Hurvitz S. Andre F. Jiang Z. Shao Z. Neciosup S. Mano M. et al. (2014) Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Poster presentation, S6–01, San Antonio Breast Cancer Symposium, December 2014.
40. Hurvitz S. Dirix L. Kocsis J. Bianchi G. Lu J. Vinholes J. et al. (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157–1163.
41. Jankowitz R. Abraham J. Tan A. Limentani S. Tierno M. Adamson L. et al. (2013) Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP foundation research program phase I study. Cancer Chemother Pharmacol 72: 1205–1212.
42. Joensuu H. Bono P. Kataja V. Alanko T. Kokko R. Asola R. et al. (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FINHER trial. J Clin Oncol 27: 5685–5692.
43. Konecny G. Meng Y. Untch M. Wang H. Bauerfeind I. Epstein M. et al. (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706–1716.
44. Konecny G. Pegram M. Venkatesan N. Finn R. Yang G. Rahmeh M. et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630–1639.
45. Krop I. Kim S. González-Martín A. Lorusso P. Ferrero J. Smitt M. et al. (2014) Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15: 689–699.
46. Krop I. Lin N. Blackwell K. Guardino E. Huober J. Lu M. et al. (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26: 113–119.
47. Leung D. Cachianes G. Kuang W. Goeddel D. Ferrara N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309.
48. Lewis Phillips G. Li G. Dugger D. Crocker L. Parsons K. Mai E. et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–9290.
49. Lin N. Dieras V. Paul D. Lossignol D. Christodoulou C. Stemmler H. et al. (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15: 1452–1459.
50. Lin N. Seah D. Gelman R. Desantis S. Mayer E. Isakoff S. et al. (2013) A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat 139: 403–410.
51. Lin N. Winer E. Wheatley D. Carey L. Houston S. Mendelson D. et al. (2012) A phase II study of afatinib (BIBW 2992), an irreversible Erbb family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133: 1057–1065.
52. Lu C. Wyszomierski S. Tseng L. Sun M. Lan K. Neal C. et al. (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13: 5883–5888.
53. Lu Y. Zi X. Zhao Y. Mascarenhas D. Pollak M. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857.
54. Martin M. Bonneterre J. Geyer C. Jr. Ito Y. Ro J. Lang I. et al. (2013) A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 49: 3763–3772.
55. Martin M. Makhson A. Gligorov J. Lichinitser M. Lluch A. Semiglazov V. et al. (2012) Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 17: 469–475.
56. Marty M. Cognetti F. Maraninchi D. Snyder R. Mauriac L. Tubiana-Hulin M. et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M 77001 study group. J Clin Oncol 23: 4265–4274.
57. Metro G. Foglietta J. Russillo M. Stocchi L. Vidiri A. Giannarelli D. et al. (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22: 625–630.
58. Munster P. Krop I. Miller K. Dhindsa N. Niyijiza C. Nielsen U. et al. (2013) Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer. Poster presentation, P4–12–29, San Antonio Breast Cancer Symposium, December 2013.
59. Nahta R. Yuan L. Zhang B. Kobayashi R. Esteva F. (2005) Insulin-like growth factor-I receptor / human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118–11128.
60. Nielsen D. Kumler I. Palshof J. Andersson M. (2013) Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22: 1–12.
61. Nordstrom J. Gorlatov S. Zhang W. Yang Y. Huang L. Burke S. et al. (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res 13: R123.
62. Pegram M. Tan-Chiu E. Miller K. Rugo H. Yardley D. Liv S. et al. (2014) A single-arm, open-label, phase 2 study of MGAH 22 (Margetuximab) [fc-optimized chimeric anti-HER2 monoclonal antibody (mAb)] in patients with relapsed or refractory advanced breast cancer whose tumors express HER 2 at the 2+ level by immunohistochemistry and lack evidence of HER 2 gene amplification by FISH. J Clin Oncol 32(Suppl. 15): abstract TPS671.
63. Perez E. Romond E. Suman V. Jeong J. Sledge G. Geyer C. Jr. et al. (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752.
64. Phillips G. Fields C. Li G. Dowbenko D. Schaefer G. Miller K. et al. (2014) Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20: 456–468.
65. Pivot X. Manikhas A. Zurawski B. Chmielowska E. Karaszewska B. Allerton R. et al. (2015) Cerebel (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33: 1564–1573.
66. Rabindran S. Discafani C. Rosfjord E. Baxter M. Floyd M. Golas J. et al. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958–3965.
67. Robert N. Leyland-Jones B. Asmar L. Belt R. Ilegbodu D. Loesch D. et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786–2792.
68. Rugo H. (2004) Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9(Suppl. 1): 43–49.
69. Saura C. Garcia-Saenz J. Xu B. Harb W. Moroose R. Pluard T. et al. (2014) Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 32: 3626–3633.
70. Scheuer W. Friess T. Burtscher H. Bossenmaier B. Endl J. Hasmann M. (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330–9336.
71. Seidman A. Berry D. Cirrincione C. Harris L. Muss H. Marcom P. et al. (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 26: 1642–1649.
72. Siegel R. Miller K. Jemal A. (2015) Cancer statistics, 2015. CA Cancer J Clin 65: 5–29.
73. Slamon D. Clark G. Wong S. Levin W. Ullrich A. Mcguire W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
74. Slamon D. Eiermann W. Robert N. Pienkowski T. Martin M. Press M. et al. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273–1283.
75. Slamon D. Godolphin W. Jones L. Holt J. Wong S. Keith D. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
76. Slamon D. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
77. Slamon D. Swain S. Buyse M. Martin M. Geyer C. Im Y. et al. (2013) Primary results from beth, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive, or high-risk node-negative breast cancer. Post Presentation: S1–03, San Antonio Breast Cancer Symposium, December 2013.
78. Sutherland S. Ashley S. Miles D. Chan S. Wardley A. Davidson N. et al. (2010) Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br J Cancer 102: 995–1002.
79. Swain S. Baselga J. Kim S. Ro J. Semiglazov V. Campone M. et al. (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372: 724–734.
80. Swain S. Baselga J. Miles D. Im Y. Quah C. Lee L. et al. (2014) Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study cleopatra. Ann Oncol 25: 1116–1121.
81. Swain S. Kim S. Cortés J. Ro J. Semiglazov V. Campone M. et al. (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (Cleopatra Study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461–471.
82. Tolaney S. Burris H. Gartner E. Mayer I. Saura C. Maurer M. et al. (2015) Phase I / II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat 149: 151–161.
83. Torre L. Bray F. Siegel R. Ferlay J. Lortet-Tieulent J. Jemal A. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87–108.
84. Tripathy D. Slamon D. Cobleigh M. Arnold A. Saleh M. Mortimer J. et al. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063–1070.
85. Verma S. Miles D. Gianni L. Krop I. Welslau M. Baselga J. et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–1791.
86. Vogel C. Cobleigh M. Tripathy D. Gutheil J. Harris L. Fehrenbacher L. et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.
87. von Minckwitz G. Du Bois A. Schmidt M. Maass N. Cufer T. de Jongh F.E. et al. (2009) Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 27: 1999–2006.
88. von Minckwitz G. Schwedler K. Schmidt M. Barinoff J. Mundhenke C. Cufer T. et al. (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer 47: 2273–2281.
89. Yen L. You X. Al Moustafa A. Batist G. Hynes N. Mader S. et al. (2000) Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19: 3460–3469.